Komori
Alfresa Holdings (2784) · FactFirst stated

Lower revenue and profit in the wholesale business for prescription drugs and other products in Q1 FY2022

First written in FY2022-Q1. . Latest entry: FY2022-Q1.

1entries
1years
0from disclosures
Share on X
How it moved
Same theme, other companies
Lower revenue and earnings in the wholesale business for prescription drugs and other pharmaceuticalsA theme 1 companies write about · 1 as a headwind · 0 as a tailwind

No other company in this theme has enough history to compare yet.

Full recordFilings, disclosures and news, newest first
  1. FY2022-Q1First statedAnnual report

    「当セグメントの当第１四半期連結累計期間の業績は、このような状況のなか、売上高5,676億88百万円、営業利益30億13百万円となりました。」

    医療用医薬品等卸売事業は、感染拡大、中間年薬価改定、入札指名停止等の影響があるなか、売上高5,676億88百万円、営業利益30億13百万円となった。
Moved together

None of this company's other threads moved the same way in the same document twice or more.

When this could move next
No upcoming earnings preview for Alfresa Holdings yet.
News
No news is linked to this thread yet. When an article touches it, it will appear here by date.